NASDAQ$TNYA
Tenaya Therapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Tenaya Therapeutics' financial performance and business progress were reported for Q1 2024.
Tenaya Therapeutics reported a net loss of $32.2 million for the first quarter of 2024. The company's cash, cash equivalents, and investments totaled $122.2 million, expected to fund operations into the second half of 2025. Clinical trials for TN-201 and TN-401 are ongoing, with initial data from the MyPEAK-1 trial expected in the second half of 2024.
- Enrollment continues in the MyPEAK-1 Phase 1b clinical trial of TN-201, with initial data expected in the second half of 2024.
- Clinical sites activated for the RIDGE-1 Phase 1b clinical trial of TN-401, with patient dosing planned for the second half of 2024.
- Cost containment measures announced, including a workforce reduction of approximately 22%.
- Net proceeds of $46.8 million raised in a first-quarter financing, extending the cash runway into the second half of 2025.
Headline financials
Revenue & EPS history
Tenaya Therapeutics · Revenue · Quarterly
$0
Forward guidance
Tenaya Therapeutics expects current cash, cash equivalents and investments in marketable securities will be sufficient to fund the company into the second half of 2025. The company will focus on dosing patients and generating clinical data for its TN-201 and TN-401 programs.
Tailwinds
- Cash runway extends into the second half of 2025.
- Focus on generating clinical data for TN-201.
- Focus on generating clinical data for TN-401.
- Advancing a pipeline of novel therapies.
- Sites activated for RIDGE-1 Phase 1b clinical trial of TN-401
Headwinds
- Committed plan to reduce its workforce by approximately 22%.
- Net loss of $32.2 million for the first quarter of 2024.
- Cost containment measures implemented.
- Reliance on clinical trial data for future progress.
- Early stage company with associated risks.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q1 2024
+2.8%
Avg return
Earnings day
+2.1%
Avg return
5 days after
-5.6%
Avg return
30 days after
50%
9 / 18 earnings
Positive
+39.8%
Q3 2022
Best reaction
-18.7%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.8% | +30.3% | -4.2% | |
| Q4 2025 | -1.3% | -0.2% | -19.7% | |
| Q3 2025 | -1.4% | -7.0% | -4.9% | |
| Q1 2025 | +7.8% | -3.3% | +38.2% | |
| Q4 2024 | -6.5% | -12.7% | -38.4% | |
| Q3 2024 | +17.4% | +20.7% | +68.1% | |
| Q1 2024 | -0.7% | +8.9% | -12.6% | |
| Q4 2023 | -8.9% | -5.1% | -13.6% | |
| Q3 2023 | -7.8% | -10.2% | -2.9% | |
| Q2 2023 | +7.3% | +0.0% | -24.6% | |
| Q1 2023 | +12.1% | +7.2% | +9.0% | |
| Q4 2022 | -18.7% | -20.6% | -25.9% | |
| Q3 2022 | +39.8% | +53.4% | +11.0% | |
| Q2 2022 | +1.5% | +6.5% | -11.3% | |
| Q1 2022 | -5.7% | -6.7% | -29.9% | |
| Q4 2021 | +6.0% | +3.2% | -5.0% | |
| Q3 2021 | +7.7% | -13.5% | -28.1% | |
| Q2 2021 | -2.8% | -12.6% | -6.5% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro